SOLV
Solventum CorporationNYSEHealthcare$63.57-1.21%ClosedMarket Cap: $11.03B
As of 2026-04-06
Valuation
P/E (TTM)
7.09
PEG
0.03
P/B
2.19
P/S
1.32
EV/EBITDA
5.40
DCF Value
$179.28
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.5%
Operating Margin
26.2%
Net Margin
18.7%
ROE
36.7%
ROA
25.9%
ROIC
17.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.00B | 49.3% | $1.68B | $63.0M | $0.37 | — |
| FY 2025 | $8.32B | 53.5% | $2.18B | $1.56B | $8.88 | — |
| Q3 2025 | $2.10B | 56.2% | $137.0M | $1.27B | $7.22 | — |
| Q2 2025 | $2.16B | 54.4% | $214.0M | $90.0M | $0.51 | — |
| Q1 2025 | $2.07B | 53.8% | $152.0M | $137.0M | $0.78 | — |
| Q4 2024 | $2.08B | 53.9% | $136.0M | $31.0M | $0.18 | — |
| FY 2024 | $8.25B | 55.6% | $1.04B | $479.0M | $2.76 | — |
| Q3 2024 | $2.08B | 56.0% | $275.0M | $122.0M | $0.70 | — |
| Q2 2024 | $2.08B | 54.6% | $244.0M | $89.0M | $0.51 | — |
| Q1 2024 | $2.02B | 58.1% | $381.0M | $237.0M | $1.37 | — |
| Q4 2023 | $2.04B | 56.9% | $406.0M | $272.0M | $1.57 | — |
| FY 2023 | $8.20B | 57.3% | $1.69B | $1.35B | $7.79 | — |